A growing number of governments hope to clone America’s DARPA
They will not succeed unless they adopt the spirit which motivates it
USING MESSENGER RNA to make vaccines was an unproven idea. But if it worked, the technique would revolutionise medicine, not least by providing protection against infectious diseases and biological weapons. So in 2013 America’s Defence Advanced Research Projects Agency (DARPA) gambled. It awarded a small, new firm called Moderna $25m to develop the idea. Eight years, and more than 175m doses later, Moderna’s covid-19 vaccine sits alongside weather satellites, GPS, drones, stealth technology, voice interfaces, the personal computer and the internet on the list of innovations for which DARPA can claim at least partial credit.
This article appeared in the Science & technology section of the print edition under the headline “Cloning DARPA”
More from Science & technology
High-tech antidotes for snake bites
Genetic engineering and AI are powering the search for antivenins
Can you breathe stress away?
Scientists are only beginning to understand the links between the breath and the mind
The Economist’s science and technology internship
We invite applications for the 2025 Richard Casement internship
A better understanding of Huntington’s disease brings hope
Previous research seems to have misinterpreted what is going on
Is obesity a disease?
It wasn’t. But it is now
Volunteers with Down’s syndrome could help find Alzheimer’s drugs
Those with the syndrome have more of a protein implicated in dementia